PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperparathyroidism |
| Phenotype | C0022658|kidney disease |
| Sentences | 40 |
| PubMedID- 22930877 | Secondary hyperparathyroidism in patients with chronic kidney disease (ckd) is common and usually caused by associated metabolic abnormalities, in particular, hypocalcaemia and hyperphosphataemia. |
| PubMedID- 20435429 | Tptx should be considered a safe and successful procedure for the treatment of severe secondary hyperparathyroidism associated with chronic kidney disease. |
| PubMedID- 22015443 | The successful management of severe forms of secondary hyperparathyroidism (shp) in patients with chronic kidney disease (ckd) may prove impossible based on medical therapy alone owing to contraindications to drug treatment, medication intolerance and non-compliance. |
| PubMedID- 22503212 | Background: cinacalcet (krn1493) was developed to manage secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 26429172 | Vascular calcifications represent a severe complication of secondary hyperparathyroidism in patients with chronic kidney disease (ckd) stage 5. |
| PubMedID- 26380158 | The exception to this trend was cinacalcet, a calcimimetic that is used to treat secondary hyperparathyroidism in patients with kidney disease receiving dialysis. |
| PubMedID- 22293059 | Vitamin d analogs are used for treatment of secondary hyperparathyroidism in patients with chronic kidney disease in order to prevent renal osteodystrophy, bone fracture and pain. |
| PubMedID- 25984155 | Hyperphosphataemia is an established risk factor for cardiovascular mortality, renal osteodystrophy and secondary hyperparathyroidism in patients with end-stage chronic kidney disease (ckd) under renal replacement therapy. |
| PubMedID- 22216316 | Additionally, poor nutritional status, vitamin d deficiency and hyperparathyroidism in patients with chronic kidney disease contribute to impaired immunity [6], [7]. |
| PubMedID- 23760489 | Synthetic analogs of 1,25(oh) 2d that are less calcemic, such as paricalcitol (19-nor-1,25-dihydroxyvitamin d 2), are used to treat hyperparathyroidism associated with chronic kidney disease. |
| PubMedID- 25028644 | The development of calcimimetics, which are synthetic allosteric modulators of the calcium-sensing receptor (car), has been a breakthrough in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (ckd). |
| PubMedID- 21832979 | Alfacalcidol and paricalcitol are vitamin d analogs used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, but have known dose-dependent side effects that cause hypercalcemia and hyperphosphatemia. |
| PubMedID- 21885174 | Background: the efficacy of 25-hydroxyvitamin d (25[oh]d) supplementation versus vitamin d receptor activators for the treatment of secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stages 3 or 4 and vitamin d deficiency is unclear. |
| PubMedID- 20921291 | Such agents have been found to be extremely effective in controlling hyperparathyroidism in patients with advanced kidney disease [9] and in reducing mortality in patients on haemodialysis [10]. |
| PubMedID- 22868729 | [management of secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis in togo]. |
| PubMedID- 25949433 | This study aims to highlight the challenges in the diagnosis of hyperparathyroidism (hpt) in patients with advanced chronic kidney disease (ckd). |
| PubMedID- 24402111 | [clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease]. |
| PubMedID- 23330456 | The calcimimetic agent cinacalcet is approved for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma. |
| PubMedID- 21318141 | Until now superiority of the third generation of pth kits, measuring only the concentration of “native” 1-84-pth, has not been proven for diagnosis of primary hyperparathyroidism, at least in patients without chronic kidney disease. |
| PubMedID- 23140920 | Considering its low incidence rate of long-term relapse, "presumed" total parathyroidectomy without autotrasplantation (tp) may be indicated for secondary hyperparathyroidism (2hpt) in patients with chronic kidney disease (ckd), not eligible for kidney transplantation. |
| PubMedID- 22022934 | Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis. |
| PubMedID- 23703334 | Particular attention is paid on this topic in nephrology, because vitamin d is routinely used to treat secondary hyperparathyroidism in patients with chronic kidney diseases1236. |
| PubMedID- 22997972 | Background: secondary hyperparathyroidism develops frequently with chronic kidney disease (ckd) and is associated with poor outcome. |
| PubMedID- 21695192 | In the clinical settings, administration of 1,25(oh)2d3 is currently used as a standard of care treatment combating both 1,25(oh)2d3 deficiency and secondary hyperparathyroidism in children with chronic kidney disease-mineral and bone disorder (ckd-mbd) [9]. |
| PubMedID- 23018042 | In chronic kidney disease patients with secondary hyperparathyroidism (shpt), the recommended k/doqi target serum levels of parathyroid hormone (pth), calcium (ca) and phosphorus (p) are difficult to reach and maintain stable. |
| PubMedID- 22007637 | Background: the calcimimetic cinacalcet is approved for treating secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. |
| PubMedID- 22622503 | Moreover, during the past decade, the intense research on mineral disorders, seen in the course of chronic kidney disease with secondary hyperparathyroidism, has revealed the interplay between ca(2+) and mg(2+) homeostasis. |
| PubMedID- 25949409 | In 2004, the us food and drug administration (fda) approved cinacalcet-hcl (sensipar®, amgen) for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. |
| PubMedID- 23713879 | Paricalcitol is a synthetic vitamin d2 agonist of the vdr approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd). |
| PubMedID- 22942242 | The calcium-sensing receptor (casr)-specific allosteric modulator cinacalcet has revolutionized the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 24377047 | Hifu therapy has been used in japan [50], but in other countries this therapy has been reported with contradictory results, sometimes failing [51] and sometimes showing improved results in secondary hyperparathyroidism treatment in patients with chronic kidney disease [52]. |
| PubMedID- 20090879 | The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) on dialysis. |
| PubMedID- 23222688 | In the context of a pharmacokinetic (pk)/pharmacodynamic study of cinacalcet in dialysis-dependent chronic kidney disease children with secondary hyperparathyroidism, we describe the development and validation of a new, rapid, simple, and economical liquid chromatography-tandem mass spectrometry (lc-ms/ms) micromethod for quantifying cinacalcet plasma concentrations. |
| PubMedID- 23960343 | This study was carried out to evaluate the efficacy and safety of doxercalciferol as therapy for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stage 4 in a prospective clinical trial. |
| PubMedID- 22210744 | Indeed, the second-generation calcimimetic, cinacalcet, has proven clinically useful in the treatment of chronic kidney disease patients with secondary hyperparathyroidism but is not widely used in earlier stages of renal disease due to the potential to predispose such patients to hypocalcaemia and hyperphosphatemia. |
| PubMedID- 25701941 | Gene mutations in chronic kidney disease patients with secondary hyperparathyroidism and sagliker syndrome. |
| PubMedID- 25789142 | [15] in fact, a reduction in 1,25(oh) 2d secondary to reduced 1-α hydroxylase enzyme activity contributes to the development of secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 21058933 | Importance of the field: chronic kidney disease is frequently complicated by secondary hyperparathyroidism, which causes bone disease and vascular calcification, leading to increased risk of morbidity and mortality. |
| PubMedID- 24884838 | This report describes the activity of amg 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved therapeutic for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease on dialysis. |
| PubMedID- 25446887 | Vitamin d insufficiency is prevalent in chronic kidney disease (ckd) and associated with secondary hyperparathyroidism (shpt) and increased risk of bone and vascular disease. |
Page: 1